Atika Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Atika Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-395,500	Closed	-$6.33M	–	138
2021 Q2	$6.33M	Sell	395,500 -84,500	-18%	-$1.45M	0.5%	71
2021 Q1	$8.58M	Buy	+480,000	New	+$8.29M	0.74%	60
2019 Q2	–	Sell	-65,000	Closed	-$3.09M	–	100
2019 Q1	$3.09M	Buy	+65,000	New	+$2.86M	0.63%	57
2018 Q1	–	Sell	-65,600	Closed	-$3.92M	–	91
2017 Q4	$3.92M	Buy	65,600 +8,600	+15%	+$522K	1.52%	30
2017 Q3	$2.77M	Sell	57,000 -8,000	-12%	-$436K	0.8%	53
2017 Q2	$3.42M	Sell	65,000 -30,000	-32%	-$1.4M	1.2%	27
2017 Q1	$4.31M	Sell	95,000 -1,500	-2%	-$66.9K	2.11%	13
2016 Q4	$3.65M	Sell	96,500 -3,500	-4%	-$132K	2.17%	20
2016 Q3	$3.77M	Buy	+100,000	New	+$2.21M	1.54%	21

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Atika Capital Management's AERI Position: Q3 2021 in Review

Atika Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 395,500 shares — an estimated $6.33M sold.

Atika Capital Management first reported a position in AERI in Q3 2016 and held it in 9 quarters. The position peaked at $8.58M in Q1 2021. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

Atika Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Atika Capital Management sold 395,500 Aerie Pharmaceuticals shares in Q3 2021, an estimated $6.33M.
Atika Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 9 quarters.
Atika Capital Management's Aerie Pharmaceuticals position peaked at $8.58M in Q1 2021.
137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Atika Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.